feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Ola promoter offloads shares

trending

KOSPI drops amid AI concerns

trending

Rohit Prasad exits Amazon

trending

SEBI impacts HDFC AMC share

trending

Hindustan Zinc share price climbs

trending

RCB signs Jacob Duffy

trending

UP board exam schedule

trending

KSH International IPO Update

trending

Blundell returns to Black Caps

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Science / Universal Flu Vaccine: The Future of Immunity?

Universal Flu Vaccine: The Future of Immunity?

17 Dec

•

Summary

  • New vaccine strategies aim to target conserved parts of the flu virus.
  • Researchers are exploring both antibody and T-cell responses for broader immunity.
  • Concerns exist over US funding cuts impacting future vaccine development.
Universal Flu Vaccine: The Future of Immunity?

The development of a universal flu vaccine is underway, seeking to provide broad protection against numerous strains and reduce the need for annual vaccinations. Researchers are focusing on eliciting immune responses against less mutable parts of the virus, such as the hemagglutinin stalk, a strategy showing promise in early trials. Alternative approaches involve stimulating T-cells to recognize internal viral proteins that are crucial for the virus's structure and thus less prone to mutation.

This pursuit aims to overcome the limitations of current vaccines, which face challenges due to rapid viral evolution and antigenic drift, leading to variable effectiveness. The goal is to create a vaccine that offers significantly better protection and potentially lasts for several years, a game-changer for public health. However, research efforts, including those within the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, face potential funding uncertainties.

Concerns have been raised regarding US government funding decisions that could impact vaccine research. Despite assurances about ongoing projects, researchers worry about future support and the broader implications for developing advanced vaccines for influenza and other respiratory viruses. The ultimate aim is a vaccine that could dramatically reduce flu-related illnesses and deaths, even if complete lifetime immunity remains an ambitious goal.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The NIAID's initiative aims to develop a universal flu vaccine offering broader and longer-lasting protection than current annual shots.
Florian Krammer and colleagues are trying to trick the immune system into attacking the conserved 'stalk' of the hemagglutinin protein on the flu virus.
Jonah Sacha's approach uses T cells to recognize internal flu virus proteins, providing protection against highly mutable strains.

Read more news on

Scienceside-arrow

You may also like

HHS Cuts Millions to Pediatric Group Over Vaccine Policy

16 hours ago • 3 reads

article image

US Measles Threat Grows: Elimination Status at Risk

16 Dec • 46 reads

article image

New Flu Variant Fuels Early, Aggressive Flu Season

16 Dec • 50 reads

article image

COVID Shots Slash Kid ER Visits

12 Dec • 58 reads

article image

Community Pharmacies Stock Up on Vital Flu Vaccines

13 Dec • 31 reads

article image